Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

General Committee of Teaching Hospitals and Institutes, Egypt

Status: Unknown

Conditions: Morbid Obesity

Treatments: Drug: Liraglutide Pen Injector [Saxenda]

Study type: Interventional

Funder types: Other

Identifiers

NCT05285397

Liraglutide1

Details and patient eligibility

About

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Undergone primary bariatric surgery
• Need secondary bariatric surgery due to either weight regain (regained weight to have BMI > 35) or medical associated diseases

Exclusion criteria

• Prior use of GLP-1 agonist
• Past history of pancreatitis
• Personal or family history of medullary thyroid cancer
• Pregnancy or lactation
• Acute coronary syndrome
• Hepatic or renal dysfunction
• Active malignancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Liraglutide

Experimental group

Description:

drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day

Treatment:

Drug: Liraglutide Pen Injector [Saxenda]

Control

No Intervention group

Description:

Patients with no weight loss drug intervention after bariatric surgery